Cargando…

Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness

Pulmonary arterial hypertension (PAH) is commonly treated with pulmonary arteriolar vasodilator therapy. When a patient on PAH medication is admitted to intensive care, determining how to manage their medication during the critical illness is often complicated. There may be considerations related to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muzevich, Katie M, Chohan, Hadi, Grinnan, Daniel C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331447/ https://www.ncbi.nlm.nih.gov/pubmed/25673176 http://dx.doi.org/10.1186/s13054-014-0523-z

Ejemplares similares

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
por: Franco, Veronica, et al.
Publicado: (2020)

A Novel Peptide for Immunomodulation in Pulmonary Arterial Hypertension
por: Grinnan, Daniel, et al.
Publicado: (2019)

Massive dilatation of the pulmonary artery in association with pulmonic stenosis and pulmonary hypertension
por: Morjaria, Sejal, et al.
Publicado: (2012)

Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension
por: Becker, Eva Maria, et al.
Publicado: (2013)

Improvement of pulmonary arterial compliance by pulmonary vasodilator in pulmonary hypertension from combined pulmonary fibrosis and emphysema
por: Kusaka, Kei, et al.
Publicado: (2019)

Drug repositioning in pulmonary arterial hypertension: challenges and opportunities
por: Grinnan, Daniel, et al.
Publicado: (2019)

The Role of Hyperglycemia and Insulin Resistance in the Development and Progression of Pulmonary Arterial Hypertension
por: Grinnan, Daniel, et al.
Publicado: (2016)

Effectiveness of pulmonary vasodilators on pulmonary hypertension associated with POEMS syndrome
por: Ohashi, Kana, et al.
Publicado: (2019)

Oxygen-Sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension
por: Morales-Cano, Daniel, et al.
Publicado: (2021)

Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis
por: Monfredi, Oliver, et al.
Publicado: (2016)

Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
por: Sanges, Sébastien, et al.
Publicado: (2019)

Pulmonary arterial hypertension in critically ill elderly patients
por: Zhang, Yun-yun, et al.
Publicado: (2017)

Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease
por: Chida-Nagai, Ayako, et al.
Publicado: (2020)

Pulmonary arterial hypertension due to pulmonary veno-occlusive disease in systemic sclerosis: Importance of early diagnosis and cautious use of pulmonary vasodilator therapy
por: Koito, Hitoshi
Publicado: (2012)

Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy
por: May, Adam, et al.
Publicado: (2014)

Peptide-Coated Liposomal Fasudil Enhances Site Specific Vasodilation in Pulmonary Arterial Hypertension
por: Nahar, Kamrun, et al.
Publicado: (2014)

Pulmonary Vasodilator Therapy in Children with Single Ventricle Physiology: Effects on Saturation and Pulmonary Arterial Pressure
por: Jeremiasen, Ida, et al.
Publicado: (2020)

Pulmonary vasodilator therapy in sarcoidosis‐associated pulmonary hypertension may decrease lung function decline and mortality
por: Gayen, Shameek, et al.
Publicado: (2023)

Utility of plasma volume status in ambulatory patients with pulmonary hypertension
por: Sternberg, Michael E., et al.
Publicado: (2022)

Comparison of intravenous sildenafil with inhaled nitric oxide for acute vasodilator testing in pulmonary arterial hypertension
por: Kumar, Shine, et al.
Publicado: (2022)

Adenosine as pulmonary vasodilator in ARDS
por: Molina, JM, et al.
Publicado: (1998)

Compression Stockings Improve Lower Legs Symptom in Patients with Pulmonary Artery Hypertension Treated by Pulmonary Vasodilators—A Pilot Study
por: Nakashima, Naoko, et al.
Publicado: (2023)

Acute vasodilator testing: An opportunity to advance the precision care of pulmonary hypertension
por: Cirulis, Meghan M., et al.
Publicado: (2019)

Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide
por: Sugawara, Eri, et al.
Publicado: (2017)

Prostanoid therapies in the management of pulmonary arterial hypertension
por: LeVarge, Barbara L
Publicado: (2015)

Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease
por: Gillmeyer, Kari R., et al.
Publicado: (2021)

The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis
por: Shu, Tingting, et al.
Publicado: (2021)

Children with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension Treated with Pulmonary Vasodilators—The Pediatric Cardiologist Point of View
por: Migdał, Anna, et al.
Publicado: (2021)

Beneficial Effects of Pulmonary Vasodilators on Pre-Capillary Pulmonary Hypertension in Patients with Chronic Kidney Disease on Hemodialysis
por: Kimuro, Keiji, et al.
Publicado: (2022)

Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries
por: Jain, Pritesh P, et al.
Publicado: (2014)

Inhaled pulmonary vasodilators in refractory hypoxemia
por: Wright, Brian J.
Publicado: (2015)

Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis
por: Langleben, David, et al.
Publicado: (2017)

Right Ventricular Postsystolic Strain Curve Morphology before and after Vasodilator Treatment in Idiopathic Pulmonary Arterial Hypertension
por: Rodríguez-Pérez, Álvaro, et al.
Publicado: (2022)

Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study
por: Naranjo, Mario, et al.
Publicado: (2023)

Management of Pulmonary Arterial Hypertension
por: Mayeux, Jennalyn D., et al.
Publicado: (2020)

Vasodilator therapy for pulmonary hypertension in children: a national study of patient characteristics and current treatment strategies
por: Jeremiasen, Ida, et al.
Publicado: (2021)

Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis
por: Kalra, Rajat, et al.
Publicado: (2020)

Pulmonary vasodilation in acute pulmonary embolism – a systematic review
por: Lyhne, Mads Dam, et al.
Publicado: (2020)

The role of combination therapy in managing pulmonary arterial hypertension
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2014)

The limits of oral therapy in pulmonary arterial hypertension management
por: Liu, Qian-Qian, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7dditg6di1u0tvso3uhv4bmbdj